Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial
Volume: 74, Issue: 5, Pages: 713 - 715
Published: Nov 1, 2019
Abstract
The prevalence of diabetic kidney disease among US adults with diabetes has remained steady at ∼25% over the last 20 years despite increased use of glucose-lowering medications and renin-angiotensin-aldosterone system (RAAS) inhibitors.1Afkarian M. Zelnick L.R. Hall Y.N. et al.Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014.JAMA. 2016; 316: 602-610Crossref PubMed Scopus (512) Google Scholar The presence of...
Paper Details
Title
Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial
Published Date
Nov 1, 2019
Volume
74
Issue
5
Pages
713 - 715
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History